The present invention provides a preparation for treatment or prevention of a condition in a patient, said preparation comprising Schisandrin B. The concentration of Schisandrin B in the preparation may be between about 0.01 and about 0.1%, or it may be between about 20 and about 40% w/w or w/v. The preparation may additionally comprise one or more components selected from the group consisting of herbal extracts, fluids, solvents, antioxidants, preservatives, electrolytes, salts and pH control agents.